Hoth Therapeutics (NASDAQ:HOTH) Upgraded by Wall Street Zen to Hold Rating

Hoth Therapeutics (NASDAQ:HOTH) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, D. Boral Capital reissued a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a research report on Thursday, June 26th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Hoth Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $4.00.

Hoth Therapeutics Stock Performance

Hoth Therapeutics stock opened at $1.21 on Friday. The business’s 50-day simple moving average is $1.06 and its two-hundred day simple moving average is $1.06. The company has a market cap of $15.92 million, a PE ratio of -1.06 and a beta of 0.67. Hoth Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.07. As a group, analysts predict that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Hoth Therapeutics

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC grew its stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 95,946 shares of the company’s stock after buying an additional 13,038 shares during the quarter. Geode Capital Management LLC owned 1.39% of Hoth Therapeutics worth $72,000 as of its most recent SEC filing. Institutional investors and hedge funds own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.